Slide 1: Q2 2020 Earnings Conference Call
Q2 2020 Earnings Conference Call July 30, 2020 ©2020 ViewRay, Inc. All rights reserved. Exhibit 99.2
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to “
Slide 3: Our Mission: Treat and Prove What Others Can't
Our Mission: Treat and Prove What Others Can’t. approaching installed systems globally1 disease sites treated1 10,000 38 >65 patients treated1 Approximately 2,200 patients with clinically reported outcomes1 12020 Internal and historical company data
Slide 4: What We Set Out to Do Two Years Ago; What We Have Accomplished
What We Set Out to Do Two Years Ago; What We Have Accomplished CLINICAL STRATEGIC ECONOMIC Customer Training Programs Clinical data compendium - publications, papers, and abstracts THEN: ~60 NOW 100+ Number of patients treated Install times: Treatment times: Prostate # of tumor types treated THEN √
Slide 5: Q2 2020 Results
Q2 2020 Results 4 MRIdian orders Revenue: $14.2 million primarily from two revenue units Used $10.7 million of cash Cash preservation actions
Slide 6: The Value of MRIdian
Mission: Treat and Prove What Others Can’t The Value of MRIdian Deliver better outcomes in hard to treat and ubiquitous cancers Shrink treatment margins to spare healthy tissue Re-optimize radiation treatment plans to safely escalate dose Reduce fractionation (e.g. 40 to 5 or fewer) and accelerate a
Slide 7: The Value of MRIdian
Mission: Treat and Prove What Others Can’t The Value of MRIdian Deliver better outcomes in hard to treat and ubiquitous cancers Shrink treatment margins to spare healthy tissue Re-optimize radiation treatment plans to safely escalate dose Reduce fractionation (e.g. 40 to 5 or fewer) and accelerate a
Slide 8: Ablative Doses to Difficult-to-treat Tumors
Ablative Doses to Difficult-to-treat Tumors MRIdian SMART lowers the risk of toxicity across multiple tumor sites ~100% ~64% SBRT & hypofractionated radiation therapy at ablative doses shown to increase toxicity MRIdian SBRT significantly decreases toxicity Up to 100% reduction in grade 3+ toxicity
Slide 9: The Future Is Now
The Future Is Now WE ARE DOING IT TODAY: MRIdian smart Cardiac sarcoma Locally advanced inoperable pancreatic cancer high dose Multiple pancreatic tumors high dose Reirradiation of ultra central lung Reirradiation of central lung Ultra central lung high dose Multiple liver mets high dose Rectal canc
Slide 10: The Future Is Now
The Future Is Now WE ARE DOING IT TODAY: mridian smart Cardiac sarcoma Locally advanced inoperable pancreatic cancer high dose Multiple pancreatic tumors high dose Reirradiation of ultra central lung Reirradiation of central lung Ultra central lung high dose Multiple liver mets high dose Rectal canc
Slide 11: The Future Is Now
The Future Is Now WE ARE DOING IT TODAY: mridian smart Cardiac sarcoma Locally advanced inoperable pancreatic cancer high dose Multiple pancreatic tumors high dose Reirradiation of ultra central lung Reirradiation of central lung Ultra central lung high dose Multiple liver mets high dose Rectal canc
Slide 12: The Future Is Now
The Future Is Now WE ARE DOING IT TODAY: MRidian smart Cardiac sarcoma Locally advanced inoperable pancreatic cancer high dose Multiple pancreatic tumors high dose Reirradiation of ultra central lung Reirradiation of central lung Ultra central lung high dose Multiple liver mets high dose Rectal canc
Slide 13: KOL Perspective: Patrick Kelly, M.D. Ph.D
©2020 ViewRay, Inc. All rights reserved. When I first started treating patients on the MRIdian, I was impressed by how the system allows you to treat patients so much more precisely and safely. As I continued to treat with the MRIdian, I realized the precision and safety allows you to treat patients
Slide 14: Clinical Roadmap to Drive Adoption
Clinical Roadmap to Drive Adoption ©2020 ViewRay, Inc. All rights reserved. Innovators proving with MRIdian SMART that they can treat what they couldn’t on conventional linacs before and better treat what they already could Expand utilization of MRIdian SMART beyond early adopters by providing clini
Slide 15: Delivering Safety and Efficacy Data for Complex SBRT Adoption
Demonstrate safe ablative dose SMART for pancreatic patients Demonstrate safe ablative dose SMART for post-prostatectomy patients and superiority versus conventional linac Today Tomorrow Future Pancreas Cancer Prostate Cancer Metastatic Cancer Delivering Safety and Efficacy Data for Complex SBRT Ado
Slide 16: Delivering Safety and Efficacy Data for Complex SBRT Adoption
Today Tomorrow Future Pancreas Cancer Prostate Cancer Metastatic Cancer Delivering Safety and Efficacy Data for Complex SBRT Adoption AUMC Pancreas Randomized Controlled Trial UCLA Intact Prostate Head-to-head MRIdian vs CT Linac Randomized Controlled Trial Study Phase: Start Up Study Phase: ENROLLI
Slide 17: MRIdian SMART Adoption
MRIdian SMART Adoption ©2020 ViewRay, Inc. All rights reserved. RETHINKING RT FUNDAMENTALS, FUNDAMENTALLY CHANGING THE GAME Prostate Patients Pancreas Patients Metastatic Patients Hundreds of thousands new MRIdian SMART patients in the US alone
Slide 18: Positioning to Win
Clarity on what will move the market Improving cash spend Driving innovation, clinical, strategic, and economic, and pipelines Positioning to Win ©2020 ViewRay, Inc. All rights reserved.
Slide 19: Q2 2020 Financial Review
Q2 2020 Financial Review 4 MRIdian orders Revenue: $14.2 million primarily from two revenue units Backlog grew to $232.2 million Cash balance: $179.5 million Used $10.7 million of cash $
Slide 20: em © VIEW RAY |VISIBLY BETTER’ | qe
em © VIEW RAY |VISIBLY BETTER’ | qe